Welcome to CoronaPod. In this show, we're going to bring you nature's take on the latest COVID-19 developments.

And we'll be speaking to experts around the world about research during the pandemic.

I really don't know how this plays out. We also don't know a ton about this, you know, virus. So there's so many open

questions. I just have a really hard time making predictions because I don't know how the outbreak's

going to change. Hello and welcome to episode 11 of CoronaPod. My name's Noah Baker,

and I'm joined by Features editor Richard Van Norton. Unfortunately, CoronaPod regular Amy Maximum is not able to be with us this week,

but Richard and I are going to power on anyway and see if we can bring you some latest news.

Richard, how's your week been?

Yeah, it's been pretty good, thanks, Noah.

I had the day off on Monday.

Went for a long walk, so I'm rejuvenated. Rejuvenated. I think as far as one

can be rejuvenated at the moment. That's right. So this week, we're going to talk about something

that we have actually talked about before on CoronaPod, but we're going to dig into a little bit,

which is hydroxychloroquine. Now, this is a potential treatment for COVID-19, which has been

bandied about by many people. There are lots and lots of trials and studies that have been going,

and this week there's been a whole new development or a whole new series of developments with

hydroxychloroquine. So first off, I think the biggest news has been there was a paper release from

the Lancet of a large observational study. Richard, tell me what's going on with that. Yeah, so this paper

was a huge study, but it was observational, as you say, meaning that it's not a randomised

controlled trial. They're not dividing their patients randomly

into matched groups and giving some hydroxychloroquine and some not without knowing who.

That's the gold standard. That's some of the trials underway. This, they just looked at many

...